Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Empagliflozin adjunctive therapy for obsessive-compulsive disorder
IRCT20240529061948N1Phase 3Completed
- Sponsor
- Alborz University of Medical Sciences
- Start
- Jun 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in obsessive compulsive disorder (OCD) comparing Empagliflozin + fluvoxamine with Placebo + fluvoxamine (2 arms). Primary endpoint: Change in Yale-Brown Obsessive Compulsive Scale score at week 12. Started Jun 2025; status: completed.
02
Drugs
empagliflozin
03
Conditions
obsessive compulsive disorder (OCD)
Beyond the preview
Go deeper on IRCT20240529061948N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20240529061948N1.